Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Blood|August 14, 2010
Effect of FCGR2A and FCGR3A variants on CLL outcomeDavid Dornan, Olivia Spleiss, Ru-Fang Yeh, et al.
Therapeutic Advances in Hematology|October 9, 2025
Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in SpainCarlos Fernández de Larrea, Javier Loscertales, Valentín Cabañas, et al.
Leukemia & Lymphoma|August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaGraeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
Pharmaceuticals (Basel, Switzerland)|July 30, 2025
Pharmacogenetic Biomarkers of Ibrutinib Response and Toxicity in Chronic Lymphocytic Leukemia: Insights from an Observational StudyNoelia Pérez-Gómez, Antonio Sanz-Solas, Beatriz Cuevas, et al.
Blood|July 31, 2024
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 studyOthman Al-Sawaf, Sandra Robrecht, Can Zhang, et al.
The Lancet. Oncology|December 15, 2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 studyAsher Chanan-Khan, Paula Cramer, Fatih Demirkan, et al.
Biomarker Research|October 28, 2020
CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemiaCarlos Cuesta-Mateos, Patricia Fuentes, Alexandra Schrader, et al.
Blood|June 12, 2014
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemiaMartin Weisser, Ru-Fang Yeh, Guillemette Duchateau-Nguyen, et al.
Blood|August 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLOthman Al-Sawaf, Moritz Fürstenau, Adam Giza, et al.
Blood|August 24, 2012
Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopeniaTadeusz Robak, Jerzy Windyga, Jacek Trelinski, et al.
Pageof 5